melanoma

Alkermes plc (NASDAQ: ALKS) has initiated a Phase 2 trial, ARTISTRY-6, evaluating nemvaleukin alfa (nemvaleukin) monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy. Nemvaleukin, Alkermes' lead immuno-oncology candidate, is...

Shares of Idera Pharmaceuticals Inc. (NASDAQ: IDRA) plunged more than 62% in the extended session Thursday after the biopharmaceutical company said its lead drug candidate Tilsotolimod failed to meet the primary endpoint in a Phase 3 trial for anti-PD-1 refractory advanced melanoma. What Happened:...

Investors and analysts don’t seem to be in lockstep when it comes to NewLink Genetics Corp (NASDAQ: NLNK)’s potential. On Monday, the biotech firm secured Buy reiterations from Stifel Nicolaus and Cantor Fitzgerald, and last week, it earned upgrades to Buy from Jefferies and Baird...

Sensus Healthcare Inc (NASDAQ: SRTS) is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who...

Sensus Healthcare Inc (NASDAQ: SRTS) (NASDAQ: SRTSW) is a micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO...

Sensus Healthcare Inc (NASDAQ: SRTS) is micro-cap manufacturer of superficial radiation therapy (SRT) devices for the treatment of skin cancer and keloids, which went public on the Nasdaq exchange in June. Benzinga recently had the chance to chat with the company’s CEO Joseph C. Sardano, who...

BMO Capital’s M. Ian Somaiya expects higher probability of success for Incyte Corporation (NASDAQ: INCY)'s epacadostat+Keytruda trials in melanoma, given the PFS strength in the updated Phase I data presented at the meeting of the European Society for Medical Oncology. Somaiya maintains an...

Argus has lifted Merck & Co., Inc. (NYSE: MRK)'s EPS estimates for 2017 from $4.00 to $4.10 due to the company's strong drug pipeline. The analysts elaborated that the pipeline includes an expected increase in sales of Keytruda, a melanoma treatment drug used on President Jimmy Carter, which...

The latest data from TickerTags provides some surprising insight into the major impact former President Jimmy Carter’s melanoma diagnosis and treatment has had on the social media popularity of Merck & Co., Inc. (NYSE: MRK)’s Keytruda. TickerTags monitors social media sites to...